TB4 Peptide Market 2026: $850M Projected Growth Driven by Wound Healing & Ophthalmic Clinical Advances
Published: July 9, 2026 14:07
Author: Stephanie Diaz
Abstract: The TB4 peptide market is projected to reach $850M by 2026, driven by clinical advances in wound healing and ophthalmology. This analysis compares leading brands (e.g., RegeneRx, Mölnlycke) on purity (>98%) and stability. TB4’s advantages include accelerated angiogenesis and anti-inflammatory effects, while limitations involve high production costs and short half-life. Key market trends favor synthetic over animal-derived peptides for regulatory compliance (FDA, EMA). Product selection criteria prioritize GMP-certified facilities, lyophilized formulations for logistics (cold chain required), and documented clinical trial data. Industry growth is underpinned by expanding applications in diabetic ulcers and dry eye disease.